Insider Selling: Santarus VP Sells 24,450 Shares of Stock (SNTS)
Santarus (NASDAQ:SNTS) VP William Denby unloaded 24,450 shares of Santarus stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $23.03, for a total transaction of $563,083.50. Following the sale, the vice president now directly owns 26,695 shares in the company, valued at approximately $614,786. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Santarus (NASDAQ:SNTS) traded down 0.84% during mid-day trading on Friday, hitting $22.39. The stock had a trading volume of 1,595,906 shares. Santarus has a 52-week low of $8.47 and a 52-week high of $28.10. The stock has a 50-day moving average of $22.88 and a 200-day moving average of $21.69. The company has a market cap of $1.486 billion and a price-to-earnings ratio of 15.74.
Santarus (NASDAQ:SNTS) last announced its earnings results on Tuesday, August 6th. The company reported $0.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.76. The company had revenue of $89.40 million for the quarter, compared to the consensus estimate of $82.90 million. During the same quarter in the previous year, the company posted $0.05 earnings per share. The company’s revenue for the quarter was up 89.4% on a year-over-year basis.
A number of analysts have recently weighed in on SNTS shares. Analysts at Leerink Swann downgraded shares of Santarus (NASDAQ:SNTS) from an “outperform” rating to a “market perform” rating in a research note to investors on Thursday, August 22nd. They now have a $26.00 price target on the stock. They noted that the move was a valuation call. Separately, analysts at JMP Securities raised their price target on shares of Santarus (NASDAQ:SNTS) from $27.00 to $31.00 in a research note to investors on Wednesday, August 7th. Finally, analysts at Zacks downgraded shares of Santarus (NASDAQ:SNTS) from an “outperform” rating to a “neutral” rating in a research note to investors on Thursday, July 25th. They now have a $27.80 price target on the stock. Two research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $25.63.
Santarus, Inc (NASDAQ:SNTS) is a specialty biopharmaceutical company focused on acquiring, developing and commercializing products that address the needs of patients treated by physician specialists.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.